Knowledge HQ

Protocols

ExCellerate NK Media Feeder-Cell G-Rex Culture Process

Download the ExCellerate NK Media Feeder-Cell G-Rex Culture Process
Download
Protocols

ExCellerate NK Media Feeder-Free G-Rex Culture Protocol

Download the protocol to support a feeder-free process in G-Rex cell culture.
Download
Literature

ExCellerate NK Media Flyer

ExCellerate NK Media offers a robust and versatile solution for NK cell cultures, designed to transition from research to clinical application seamlessly.
Download
Literature

Liquid Cytokines Brochure

Streamline your cell culture process with our new liquid frozen formulations of animal-free RUO and GMP IL-2, IL-7, and IL-15. These ready-to-use cytokines eliminate reconstitution errors while still providing the same potency and consistency as our lyophilized proteins. Simply thaw and add to your cell culture.
Download
Application Notes

CAR NK-92 cell–mediated depletion of residual TCR+ cells

Utilization of G-Rex by introducing a new scalable depletion method: Coculturing target CAR T cells with an NK-92 cell line in G-Rex to purify their CAR T cells and promote CAR T cell expansion at the same time.
Read More
Publications

Development of large-scale expansion protocol for NKG2C-positive NK cells for treatment of glioblastoma

This study presents a protocol for large-scale expansion of NKG2C+ NK cells using PC-3 feeder cells. G-Rex 6M well plates were employed to achieve high expansion factors (median 358.5-fold) of functional NK cells for glioblastoma immunotherapy.
Download Now
Webinars

Marker TX T-cell Manufacturing Simplification

Join Anastasiya Smith, Snr. Director of R&D at Marker Therapeutics for a 15-minute pre-recorded webinar covering the first critical steps in successful automation through simplification with the G-Rex platform.
View Webinar
Literature

Proven Process

This is our proven process illustrating how ScaleReady works in a true partnership with your T and NK cell therapy program to enable the successful commercialization of your drug. This is a linear left-to-right, as well as a holistic view, of how at every stage, we look to simplify, streamline, and scale by offering expertise and support for your cell therapy program. Through our proven process, we deliver practical and viable solutions by providing the most simple, scalable, and versatile manufacturing products. Our process is proven, as our products are represented in approved CAR-T drugs around the globe.
Download
Literature

RUO and GMP IL-2 Cytokine Brochure

GMP Recombinant Human IL-2 joins IL-7 and IL-15 produced within Bio-Techne’s dedicated animal-free GMP facility located in St. Paul MN USA. Our GMP-grade IL-2 contains the same cysteine to serine mutation found in Proleukin®. This mutation has been reported to prevent cysteine mispairing in E.coli, which can lead to protein aggregation and makes our new GMP-grade IL-2 protein soluble in injectable-grade water.
Download
Literature

IL-2, IL-7 and IL-15 Cytokines Brochure

IL-2, IL-7, and IL-15 are critical cytokine components to many successful T and NK cell therapy programs.  Choosing these cytokines from a partner that can offer seamless translation from RUO to GMP means that the consistency across lots, the confidence in bioactivity, and cost-effectiveness are no longer barriers to manufacturing with consistency, translating with speed and scaling without limitation.  Learn more about these powerhouse cytokines in this brochure.
Download
Literature

Recombinant Human IL-7 GMP

GMP-grade Recombinant Human IL-7 can now be produced at a game-changing scale within Bio-Techne’s new dedicated animal-free GMP facility. This flyer details manufacturing benefits and product specifications for GMP IL-7, including comparison to animal-free research-grade rhIL-7 to enable a seamless transition to GMP.
Download
Case Studies

Transition to Closed-system T Cell Expansion Leads to Process Optimization

In this case study, ScaleReady helped an autologous T cell therapy company rapidly transition to a closed-system process for cell expansion by providing a testing plan to verify that G-Rex500M-CS closed-system bioreactors would meet their immediate cell production requirements and improve cell production efficiency, while adhering to their short timelines for going into clinical trials. In doing so, the company also uncovered small changes to their cell culture protocols that made a big impact on their cell production efficiency.
Download